TerminatedPhase 2

Dose-adjusted EPOCH-R in MYC Positive DLBCL

Stopped: Poor accrual of eligible patients

China26 participantsStarted 2013-02

Plain-language summary

The aim of this study is to evaluate the efficacy and toxicity of dose-adjusted EPOCH-R in patients with MYC positive diffuse large B-cell lymphoma.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Previously untreated MYC positive diffuse large B-cell lymphoma * Age range 18-70 years old * Eastern Cooperative Oncology Group performance status 0-2 * Life expectancy of more than 3 months * Adequate organ function Exclusion Criteria: * Primary or secondary central nervous system involvement * Previous serious cardiac disease * History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * Pregnant or lactating women * Serious uncontrolled diseases and intercurrent infection

What they're measuring

3-year progression-free survival

Timeframe: 3 years

Trial details

NCT IDNCT01914718

SponsorFudan University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-12

View on ClinicalTrials.gov More Diffuse Large B-cell Lymphoma trials